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Abstract Space flight is one of the most extreme condi-
tions encountered by humans. Advances in Omics meth-
odologies (genomics, transcriptomics, proteomics, and
metabolomics) have revealed that unique differences exist
between individuals. These differences can be amplified in
extreme conditions, such as space flight. A better under-
standing of individual differences may allow us to develop
personalized countermeasure packages that optimize the
safety and performance of each astronaut. In this review,
we explore the role of ‘‘Omics’’ in advancing our ability to:
(1) more thoroughly describe the biological response of
humans in space; (2) describe molecular attributes of
individual astronauts that alter the risk profile prior to
entering the space environment; (3) deploy Omics tech-
niques in the development of personalized countermea-
sures; and (4) develop a comprehensive Omics-based
assessment and countermeasure platform that will guide
human space flight in the future. In this review, we advance
the concept of personalized medicine in human space
flight, with the goal of enhancing astronaut safety and
performance. Because the field is vast, we explore selected
examples where biochemical individuality might signifi-
cantly impact countermeasure development. These include
gene and small molecule variants associated with: (1)
metabolism of therapeutic drugs used in space; (2) one
carbon metabolism and DNA stability; (3) iron metabo-
lism, oxidative stress and damage, and DNA stability; and
(4) essential input (Mg and Zn) effects on DNA repair.
From these examples, we advance the case that widespread
Omics profiling should serve as the foundation for aero-
space medicine and research, explore methodological
considerations to advance the field, and suggest why per-
sonalized medicine may become the standard of care for
humans in space.
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1 Introduction
To date, more than 600 civilians have registered to fly into
space aboard commercial suborbital space vehicles (D.
Durda, personal communication, June 3, 2013). That is more
than the 534 individuals that have been in Earth orbit, since
space flight began in the 1960s (NASA, NP-2005-01-001
JSC, NASA 2005, List of Space Travelers by Name 2013).
Currently, there are ambitious private sector plans to send
humans to space for mining and other high risk commercial
endeavors.
With increasing space flight participation comes
increasing heterogeneity in the flying population, extended
duration missions, and prolonged exposure to the high
radiation environment beyond low Earth orbit (BLEO).
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Highly variable risk profiles, coupled with the unusually
hostile conditions of space will force us to adopt new
human factors approaches that are commensurate with
these demands.
For instance, recent evidence has shown that some
20–25 % of the long duration astronauts on the Interna-
tional Space Station (ISS) developed persistent ocular
problems after missions of varying lengths, especially
those missions [4 months (Smith et al. 2012; Zwart et al.
2012). With this outcome, one is compelled to consider that
unique susceptibilities may exist in the affected group and
that foreknowledge of such susceptibility allows for the
development of protective or adaptive countermeasures.
Indeed, there is preliminary evidence this astronaut sub-
population may have altered one carbon metabolism, with
specific genetic and micronutrient attributes, the effects of
which are further exacerbated by the space flight
environment.
In order to preserve and enhance performance and safety
in the evolving astronaut, space scientist, and space tourist
populations, space biomedicine will increasingly be forced
to understand individual risk profiles and to develop
countermeasures that are tailored to each individual par-
ticipant (Fig. 1).
This necessarily drives us toward the emerging field of
personalized medicine. Personalized medicine uses
information about a person’s genes, proteins, and metab-
olites in the context of his or her diet, nutrition, lifestyle,
and environment to prevent, diagnose, and treat or prevent
disease. In relation to space flight, one can further state that
personalized medicine uses information about a person’s
genes, transcripts, proteins, and metabolites in the context
of his or her diet, nutrition, lifestyle, and environment to
optimize safety and performance commensurate with the
demands of a unique condition, habitat, or mission profile.
Today and in the future, personalized medicine
approaches will afford us the ability to individualize
countermeasures in an effort to improve astronaut perfor-
mance and safety. This is not aimed at restricting mission
participation. On the contrary, the approach is focused on
understanding individual astronaut profiles and on devel-
oping countermeasures that optimize the astronaut’s ability
to participate at his or her highest functional level.
In the field of human space flight, personalized medicine
has become possible, as advances in genomics, transcri-
ptomics, proteomics, metabolomics, and bioinformatics
affords us the ability to characterize individual profiles
with low cost and high precision. Because of the small
number of individuals, the high risk of mission failure, and
the extreme demands upon individuals, one can argue that
human space flight is among the most obvious environ-
ments in which to deploy personalized medicine.
Fig. 1 Personalized medicine paradigm for humans in space.
a Astronauts today receive advanced medical care, but they do not
undergo comprehensive genotyping, metabolic network assessment,
and assessment of essential small molecule inputs for the purpose of
developing countermeasures. Countermeasures are generalized across
the astronaut pool. b Under the proposed new paradigm, a compre-
hensive assessment of targeted genome, transcriptome, proteome, and
metabolome will guide countermeasure development, with each
astronaut receiving a countermeasure package tailored to the
individual and to the mission
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This review will summarize: (1) key elements of per-
sonalized medicine that are germane to human space flight,
(2) knowledge that will allow us to deploy components of
personalized medicine today, and (3) recommendations for
evolving a sophisticated platform to advance personalized
medicine for the future of human space flight.
Our goal is to address some of the most challenging
issues facing humans in space, and to explore how indi-
vidual differences may increase or decrease risk under
these unique conditions.
2 Background: systems biology, functional genomics,
gene variants, and drug metabolism in space
biomedicine
2.1 Applied systems biology in space biomedicine
Systems biology can be described as the study of the
interactions between the components of biological systems,
and how these interactions give rise to the function and
behavior of that system. In human medicine, systems
biology traditionally incorporates genomics, transcripto-
mics, proteomics, and metabolomics. Data derived from
these Omics disciplines are combined with metadata about
the subject’s: (1) environment, (2) diet, (3) nutrition, (4)
psychosocial dynamics, (5) lifestyle, (6) medical treat-
ments, (7) antecedents, (8) anthropometrics, and, in gen-
eral, (9) broad information about phenotype. Multivariate
analysis and modeling methods are applied to the high
dimensional data sets derived from these analyses, in order
to describe systems, derive meaning, and generate new
hypotheses.
In the current space biomedicine paradigm, targeted,
hypothesis-driven methods are the rule. In most cases,
molecular targets to be analyzed are preselected, based on a
guiding hypothesis. This method has served space bio-
medicine well for the duration of its history. However, it is
notably limited by the fact that targeted-analyses, by
design, fail to detect off-target, or unanticipated effects.
The strength of Omics-based, data-driven approaches is
that they afford us the ability to detect unanticipated
effects, reveal novel pathways and mechanisms, and gen-
erate new hypothesis, from which follow up targeted
analyses can be performed. This can shorten the discovery
time from decades to years and allow us much more rapid
development of countermeasures for these extreme condi-
tions. This is particularly relevant to human space flight,
because there are so few subjects.
The extreme condition of space and the complexity of
human systems warrant an emergent approach that is roo-
ted in the new systems biology paradigm. Under this
emergent model, test conditions of astronauts in Earth-
based analogue studies and actual mission conditions
would be studied using non-targeted and targeted Omics-
based methods. These methods can be used to develop
assessment and countermeasure protocols specific to each
astronaut, which would form the basis of personalized
medicine.
In this review, we build a case for Omics-based medi-
cine in human space flight that is personalized, preventive,
and predictive. Rather than being a comprehensive over-
view of the field, our discussion is centered on five con-
cepts that represent components of the systems biology
paradigm, which have immediate and near-term applica-
tion in space biomedicine. These include: (a) genetic
variants that may drive unique risk profiles of astronauts in
the general space environment; (b) genetic variants that
may alter risk and efficacy profiles of therapeutic drugs
deployed in space; (c) essential inputs into metabolism that
may raise or lower individual risk profiles in space;
(d) molecular variants that may alter individual risk profiles
in the high radiation environment of space; and (e) how
combinatorial events may aggregate to shift risk profiles.
2.2 Functional genomics and space biomedicine
The emergence of personalized medicine has been inspired,
in part, by compelling advances in genomics applied to
diagnostics and therapeutics in oncology. For instance,
molecular diagnostic tests for human epidermal growth
factor receptor 2 (HER2) are used to identify the patients
who will benefit from receiving trastuzumab (Herceptin,
Herclon) and other drugs that target HER2, such as la-
patinib (Tykerb). Over-expression of HER2 has been
shown to play an important role in the progression and
pathogenesis of certain aggressive types of breast cancer.
More recently, it has emerged to become an important
biomarker that aids in therapeutic guidance (Tanaka 2010).
Two complex diagnostic tests, Oncotype DX and
MammaPrint, use genetic information to help physicians
chart the best course of treatment for breast cancer patients.
Oncotype DX can determine whether women with certain
types of breast cancer are likely to benefit from chemo-
therapy (Tanaka 2010). MammaPrint can determine which
early-stage breast cancer patients are at risk of distant
recurrence following surgery (Pers Med Coalition 2010).
Both tests place patients into risk categories that inform
physicians and patients whether their cancer may be treated
successfully with hormone therapy alone or whether a
more aggressive treatment is needed.
Current advances in systems biology and personalized
medicine now afford us the ability to apply similar
sophistication to astronauts entering the extreme conditions
of space. Below, we characterize a subset of genomic and
small molecule variants that are highly relevant to human
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space flight and human performance. We have limited our
discussion to these in order to simplify the discussion for
the purpose of this review. Beyond these examples, there is
extensive literature on an array of molecular variants that
are relevant to space flight today, in addition to a growing
list that we envision will become relevant with further
elucidation.
For the purposes of this review, we will explore, by
example (1) gene and small molecule variants associated
with metabolism of therapeutic drugs used in space; (2)
gene and small molecule variants associated with one
carbon metabolism; (3) gene and small molecule variants
associated with iron metabolism, oxidative stress, and
DNA stability; and (4) elemental essential input that bears
upon energy regulation, DNA repair, and oxygen utiliza-
tion in space. We conclude by examining a path whereby
systems biology may become the foundation for develop-
ing personalized medicine in human space flight.
The purpose this review is not to offer a policy docu-
ment, but rather to explore a series of core concepts from
which personalized approaches to enhance astronaut per-
formance, endurance, and safety can be developed.
3 Gene variants and drug metabolism in space
During missions, astronauts are provided with an array of
prescription drugs that are deployed based on Earth-based
clinical need. In the past, little consideration has been
given to the potential for adverse drug reactions, based on
individual genotype. However, we must now consider two
important aspects of personalized drug responses in astro-
nauts on prolonged missions. These include the potential
for adverse drug reactions and the potential that drug
efficacy can be negatively impacted by the biochemical
uniqueness of the astronaut and his environment. Either or
both can contribute to adverse health outcomes and altered
astronaut performance in space. Because of the substantial
variance possible in individual responses, it becomes
imperative that we characterize the variants in astronauts in
order to limit adverse effects on exploration missions.
While some prescription drug use will be pre-planned
based on astronaut clinical needs, the deployment of phar-
maceuticals in space flight will often be based on circum-
stantial need. Aerospace medicine physicians will want to
ensure that the risk of a pharmaceutical triggering an adverse
drug reaction in space is kept to a minimum, as extensive
medical facilities will be unavailable. This can be done by
understanding the specific drug metabolism profiles of each
individual and identifying by genotypic assessment the drugs
most likely to be poorly tolerated in each astronaut. This
profile can then be used to design the optimum personalized
drug profile, should pharmaceutical intervention be required.
The optimum drug profile can be developed by char-
acterization of Phase I (cytochrome P450) and Phase II
drug metabolism profiles.
3.1 Personalized drug regimens based on cytochrome
P450
The first such characterization of individual astronaut bio-
transformation capacity should be based on individual
cytochrome P450 (CYP450) profiles. The cytochrome P450
family (CYP450) is a major subset of drug-metabolizing
enzymes. The CYP450 family of enzymes includes, but is
not limited to, the following important genes (Wu 2011).
• CYP 2D6 is also known as debrisoquine hydroxylase,
which catalyzes the oxidation of approximately a
quarter of all the commonly used therapeutic drugs in
used clinical practice today. For instance, codeine is
metabolized by CYP2D6 to morphine. In such cases,
enhanced CYP2D6 activity (i.e., in CYP2D6 ultra-rapid
metabolizers) predisposes one to opioid intoxication
(Gasche et al. 2004).
• CYP 2C19 (S-mephenytoin hydroxylase) acts on
weakly or strongly basic drugs containing one hydrogen
bond donor, or if there are functional groups containing
carbon or sulfur double bonded to oxygen present in the
substrate. CYP 2C19 is responsible for the metabolism
of anticonvulsant drugs, proton pump inhibitors, and
drugs that inhibit platelet function.
• CYP3A4 involved in the oxidation of the largest range
of substrates of all the CYPs. It is the most abundantly
expressed P450 in human liver and it is known to
metabolize more than 120 different drugs. Examples of
CYP3A4 substrates relevant in human space flight
include: acetaminophen, diazepam, erythromycin, lido-
caine, lovastatin, and warfarin. CYP3A4 also is sensi-
tive to enzyme induction, which tends to lower plasma
concentrations of CYP3A4 substrates, resulting in
reduced efficacy of the substrate.
Some CYP450 genes are highly polymorphic, resulting
in enzyme variants that may shape variance in drug-
metabolizing capacities among individuals at Earth gravity
(1G), let alone the microgravity environment. For context,
it is estimated that genetics account for 20–95 % of vari-
ability in drug disposition and effects (Hitchen 2006).
CYP450 metabolic capacities may be described as follows
(Tama´si and Falus 2012).
Extensive metabolizers (also called Normal
Metabolizers)
• have two active CYP450 enzyme gene alleles, resulting
in an active enzyme molecule
Intermediate metabolizers
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• have one active and one inactive CYP450 enzyme gene
allele
• May require lower dosage than normal, though pro-
drugs may require higher dose
Poor metabolizers
• lack active CYP450 enzyme gene alleles
• may suffer more adverse events at usual doses of active
drugs due to reduced metabolism and increased
concentrations
• may not respond to administered pro-drugs that must be
converted by CYP450 enzymes into active metabolites
Ultrarapid metabolizers
• have 3 or more active CYP450 gene alleles
• may not reach therapeutic concentrations at usual,
recommended doses of active drugs
• may suffer adverse events from pro-drugs that must be
converted by CYP450 enzymes into active metabolites
• May require higher doses of pro-drugs
For space flight, a list can be generated identifying the
CYP450 enzymes with genetic variants of a specific indi-
vidual. This list can be cross-referenced with the particular
mission drug list. When conflicts arise between the CYP
SNP profile and the mission drug list, alternative drugs can
be selected that are metabolized via a different CYP
pathway.
The U.S. Food and Drug Administration (FDA) has
already approved a microarray device that can detect 29
variations in CYP2D6 and CYP2C19 (Shizukuda et al.
2009). Follow-on multiplex assays for (CYP2C19) and
(CYP2D6) have also been approved by the FDA.
Cytochrome P450 profiles of selected drugs that might be
found on a mission drug list are noted in Table 1.
3.2 Personalized drug regimens based on Phase II
conjugation
For many drugs, metabolism via CYP450 is the first phase
of drug biotransformation, as noted. These same drugs
frequently pass through a Phase II biotransformation
reaction. Phase II drug metabolism reactions are generally
characterized as conjugation reactions, wherein a small
molecule is bound to the drug metabolite to improve sol-
ubility for eventual excretion.
Characterization of individual astronaut Phase II profile
might consider at least three features. These are: (1) SNP
variant profiles of Phase II conjugation enzymes, (2) ade-
quacy of micronutrient cofactors of Phase II enzymes, and
(3) adequacy of conjugation agents that directly bind
drugs, as part of Phase II conjugation.
Phase II profiles should be conducted for each astronaut
and, where the evidence is sufficient, be used to develop
appropriate countermeasures. For the Phase II profile,
assessment considerations include, but are not limited to:
SNP variant profiles of Phase II conjugation enzymes
For instance, UGT (UDP glucuronosyltransferases) is an
enzymatic superfamily, which is involved in conjugation of
endogenous compounds (bilirubin, steroidal hormones,
thyroid hormones, biliary acids, vitamins) and exogenous
compounds (drugs, carcinogens, polluting dietary ele-
ments) that are transformed in N-, O-, S-, C-glucuronates.
They are responsible for roughly 35 % of Phase II reac-
tions. Understanding genetic variants of Phase II enzymes
Table 1 Substrates, inhibitors, and inducers of human CYP450s
CYP1A2 CYP2B6 CYP2C9 CYP2C19 CYP2D6 CYP2E1 CYP3A4
Substrates Caffeine Bupropion Diclofenac Omeprazole Bufuralol Acetaminophen Nifedipine
Imipramine Midazolam Losarten Phenytoin Codeine Ethanol Erythromycin
Tacrine Tamoxifen Phenytoin Indomethacin Desipramine Chlorzoxazone Midazolam
Theophylline Verapamil Tolbutamide R-warfarin Lidocaine Sevoflurane Testosterone
R-warfarin Testosterone S-warfarin
Inhibitors Ciprofloxacin Ketoconazole Fluconazole Cimetidine Quinidine Disulfiram Ketoconazole
Furafylline Tranylcypromine Sulfaphenazole Ketoconazole Methadone Erthyromycin
Mibefradil Troglitazone Paroxetine Paroxetine Cimetidine Grapefruit
juice






















A partial list of CYP450 inhibitors, substrates, and inducers. For a complete list, see (Flockhart 2007)
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will be helpful in designing individualized drug regimens
(Crettol et al. 2010).
Adequacy of nutrient cofactors of Phase II enzymes For
instance, riboflavin is a cofactor for glutathione reductase.
Assess pre-mission status of all nutrient cofactors to ensure
optimum status for each individual astronaut. If warranted
by genotype, provide nutrient cofactor at dosage com-
mensurate with the allelic variant (e.g. wild type, hetero-
zygote, homozygote).
Conjugation agents that directly bind drugs, as part of
Phase II conjugation Assess pre-mission status of key
conjugation agents (e.g. glutathione, glycine, cysteine,
glutamine, arginine, taurine, acetate) to ensure optimum
status for that individual. For example, in most cases of
glutathione conjugation, more polar glutathione conjugates
are eliminated into the bile or are subsequently subjected to
other metabolic steps. This eventually leads to formation of
mercapturic acids, which are excreted in urine. In these
cases, glutathione is depleted as it binds drugs through the
conjugation of Phase I intermediate metabolites. This
depletion can reduce available glutathione for future drug
metabolism reactions and alter the redox balance of the
cell.
For instance, the analgesic acetaminophen is converted
to the electrophilic N-acetyl-p-benzoquinone imine (NAP-
QI), which is conjugated for removal by glutathione. If
glutathione is in poor supply, NAPQI exerts highly toxic
effects by covalent reactions with proteins, such as those
found in mitochondria. This can lead to liver damage (Ja-
eschke and Bajt 2006).
If glutathione depletion is identified through blood
chemistry (low GSH or low GSH:GSSG ratio), pre-mission
glutathione or glutathione precursors can be provided at the
dosage needed to assure optimum mission status. Stable
glutathione precursors, such as N-acetylcysteine, can be
provided on missions.
3.3 Personalized drug regimens based on ethnicity
Ethnic differences in CYP450 isoforms, such as CYP2D6
and CYP2C19, can be pronounced and warrant consider-
ation when embarking on long duration space missions. For
instance, most western populations are characterized by
roughly 93 % normal (or efficient) metabolizers, 7 % poor
metabolizers, and 1 % ultra-rapid metabolizers of
CYP2D6. In contrast, only 1 % of Asians are considered
poor metabolizers of CYP2D6. Roughly 20 % of Asians
are poor metabolizers via CYP2C19, while only about 4 %
of Caucasians are considered poor metabolizers via this
isoform (Jain 2009).
CYP3A5 expression also varies widely with ethnicity.
For instance, more than 50 % of African Americans
express CYP3A5, while some 30 % of Caucasians express
this isoform. Understanding ethnic variance in CYP func-
tionality has the potential to greatly enhance astronaut
safety and performance, by assuring that prescribed drugs
work as expected and that the probability of adverse
reaction to these drugs is minimized.
3.4 Omics and drug metabolism in space
Using pharmacogenomics and targeted metabolomics to
personalize drug prescribing, is one preventive method to
improve safety and efficacy of drugs used in space.
Assessing specific gene, protein, and metabolite changes in
response to drug administration, represents an application
of Omics that can more thoroughly characterize off-target
(or unanticipated) drug effects in space or space analogue
environments.
4 One carbon metabolism and human gene variants
on earth and in space
One carbon metabolism involves the transfer of methyl
groups (CH3) from donors, such as folate, B12, choline,
betaine, and trimethylglycine. Folate, B12, and choline are
essential inputs that must be obtained from the diet. A
deficit in methyl donors, leads to a series of adverse events
important to humans in space. The enzymes that govern
one carbon metabolism are produced from a series of
methyl transfer genes. Common polymorphisms in key
methyltransferase genes also lead to adverse events of
importance. Frequently, convergence exists between
altered micronutrient intake and genetic polymorphisms
(Fig. 2). The potential implications for human space flight
are only just emerging.
4.1 One carbon metabolism and neuro-ocular health
There is mounting evidence that specific health risks, such
as neuro-ocular changes [and increased intracranial pres-
sure (ICP)], are related to disordered one-carbon metabo-
lism involving folate, B12, and Hcy. Approximately 20 %
of ISS crew members on space flight missions of 4 months
or longer have experienced ocular changes and persistent
visual problems on return to Earth. These were correlated
with significantly elevated levels of Hcy, methylmalonic
acid and cystathionine, along with reduced levels of folate
and Vitamin B12 (Zwart et al. 2012). The metabolite data
indicate that a significant proportion of crew members may
have associated genetic traits that contribute to disturbed
one-carbon metabolism. In addition, the metabolic pathway
mutation described above has been conclusively linked to
the production of oxidative stress and damage associated
with coronary artery disease (Vijaya Lakshmi et al. 2011).
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While the link between space flight-induced ocular changes
and altered one-carbon metabolism must be replicated in
follow up studies, the existence of such a link may have
significant implications, given the altered fluid dynamics
known to occur in space flight.
Otto and colleagues have documented that 15 long-
duration crewmembers have experienced in-flight and post
flight visual and anatomical changes including optic-disc
edema, globe flattening, choroidal folds, and hyperopic
shifts as well as documented post flight elevated ICP. In the
post flight time period, some individuals have experienced
transient changes while others have experienced changes
that are persisting with varying degrees of severity.
While the underlying etiology of these changes is
unknown at this time, the NASA medical community
suspects that the microgravity-induced cephalad-fluid shift
and commensurate changes in physiology play a significant
role (NASA Evidence Report Risk of Spaceflight-Induced
Intracranial Hypertension and Vision Alterations) (Otto
2012; Mader et al. 2011). Furthermore, in retrospective
examination of data, [60 % of long-duration crewmem-
bers (ISS/MIR) and [25 % of short-duration (Shuttle)
crewmembers have reported subjective degradation in
vision (based on debrief comments) (Mader et al. 2012;
Gibson et al. 2012). Decreased near-visual acuity was
demonstrated in 46 % of ISS/Mir and 21 % of Shuttle
crewmembers, resulting in a shift of up to 1–2 diopters in
their refractive correction. It is also known that Hcy is a
causative agent in retinal ganglion cell death (Ganapathy
et al. 2011). These phenomena may have direct implica-
tions for the documented loss of vision that ISS astronauts
and other long durations flyers have experienced.
4.2 One carbon metabolism, chromosome instability,
and space radiation
A set of convergent variants in one carbon metabolism is
known to strongly influence chromosome stability via direct
effects on DNA. In nucleic acid synthesis, deoxythymidylate
(dTMP) is synthesized from deoxyuridylate (dUMP),
through one carbon transfer from a methyl donor. The methyl
donor is typically methylfolate, though methyl transfer is
also strongly influenced by B12 and choline status (choline
metabolism intersects with folate metabolism at the meth-
ylation of Hcy to form methionine) (da Costa et al. 2006).
When methyl groups are unavailable from folate, conversion
of uracil to thymine is reduced. This results in an alteration of
the dTMP/dUMP ratio and in uracil accumulation in cell
nuclei (Ames 2000) (Figs. 3, 4).
Normally, when uracil appears in DNA, it is excised by
uracil glycosylase enzymes. However, with excessive
uracil accumulation, the process can lead to transient
Fig. 2 Summary of one carbon metabolism. Dietary methionine is
converted to homocysteine (Hcy), cystathionine, and cysteine, which
can be further converted to form glutathione. Inadequate B12, folate,
or B6 may lead to elevated Hcy, with its attendant biological effects.
Depleted glutathione may impair free radical defenses, as well as the
ability to conjugate prescription drugs in space. Folate, in the form of
5,10-methylene THF, is involved in the transfer of one carbon units.
5,10-methylene THF is reduced to 5-methyl THF by MTHFR, which
is the site of very common genetic polymorphisms. The methyl group
is transferred to dUMP for dTMP synthesis, which is an irreversible
rate-limiting step in DNA biosynthesis. Sustained disruption of one
carbon metabolism results in misincorporation of uracil into the DNA
backbone in place of thymine, a change that is equivalent to a
mutational event. In general, disordered one carbon metabolism by
genetic polymorphism, micronutrient deficit, or both can lead to
several downstream effects with implications in space flight. These
include (1) elevated Hcy, (2) decreased glutathione synthesis, and (3)
unstable DNA (adapted from: Lamprecht and Lipkin 2003)
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single-strand breaks in DNA. Two opposing single-strand
breaks can lead to double-strand chromosome breaks,
which are more difficult to repair and can lead to genome
instability. Common fingerprints of such changes include
micronuclei, nucleoplasmic bridges, and nuclear buds
(Courtemanche et al. 2004).
In a small (N = 22) cross-sectional study of micronu-
cleus frequency in erythrocytes of splenectomized subjects,
Blount et al. showed that the elevated micronucleus index
was strongly associated with low levels of serum folate. In
this study, uracil levels were found to be 70 times higher in
subjects whose serum folate \4 ng/ml (as high as 4 M
uracil residues/cell). After 3 days supplementation with
5 mg folic acid, uracil levels were rapidly reduced. This
was accompanied by corresponding reductions in erythro-
cyte micronucleus frequency, though this took much longer
(Blount et al. 1997). Of interest is a finding that men with
normal concentrations of folate and vitamin B12, but Hcy
levels [10 mol/l had significantly increased micronucleus
index (p = 0.05). This was in comparison to those with
normal folate, normal vitamin B12, and Hcy \10 mol/l.
Elevated Hcy status, in the absence of vitamin deficiency,
and low, but not deficient, vitamin B12 status appear to be
important risk factors for increased chromosome damage in
lymphocytes (Fenech 2012).
Titenko–Holland conducted a folic acid depletion/
repletion study (base-line: 195 lg/day; depletion: 5 weeks
65 lg/day; repletion: 4 weeks 111 lg/day followed by
20 days [ 280 lg/day) in nine postmenopausal women in
a metabolic unit. These women showed a significant
increase in micronucleus frequency in lymphocytes fol-
lowing depletion and a decrease following repletion.
Micronucleus frequency in buccal cells decreased after the
repletion phase. The depletion phase in this study also
resulted in DNA hypomethylation, increased dUTP/dTTP
ratio, and lowered NAD levels in lymphocytes (Titenko-
Holland et al. 1998).
Fenech et al. performed a randomized double-blind
placebo-controlled dietary intervention study (N = 31, 32
per group) to determine the effect of folate and vitamin
B12 (B12) on DNA damage (micronucleus formation and
DNA methylation) and plasma Hcy in young Australian
adults aged 18–32 years. The dietary intervention involved
supplementation with 700 lg folic acid and 7 lg vitamin
B12 in wheat bran cereal for 3 months, followed by
2,000 lg folic acid and 20 lg vitamin B12 via tablets for a
Fig. 3 Methyl transfer, uracil, and thymine. A methyl group (–CH3)
is transferred from folic acid to uracil in the formation of thymine. If
methyl groups are limited in availability (via genotype, micronutrient
deficit, or both), uracil accumulates in the nucleus
Fig. 4 Uracil, unstable DNA, and radiation. a Methylation defects
lead to high nuclear uracil. Incorporation of uracil (U) into DNA
activates the uracil-DNA glycosylase repair system to repair the DNA
strand. Repair glycosylase enzymes attempt to excise the uracil
residues, which involves temporarily cleaving the DNA backbone.
However, if the ratio of dUTP to dTTP is still elevated (due to high
nuclear uracil), this re-synthesis may again incorporate uracil instead
of thymine. b This cycle may lead to DNA single strand breaks,
double strand breaks, and eventual chromosome fragmentation
(equivalent to a mutational event). c Exposure of this unstable
DNA to subsequent radiation in space (heavy ions, solar protons,
x-rays, etc.) may initiate additional DNA damage (representing two
convergent mutational events). Adapted from Be´ke´si, A 2004
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further 3 months. This study revealed that micronucleated
cell frequency is minimized when plasma Hcy is below
7.5 mol/l, serum B12 is above 300 pmol/l, and red cell
folate is above 700 nmol/l. The study also revealed that
elevated plasma Hcy may be a direct risk factor for chro-
mosome damage (Fenech 1998, 2012).
Milic´ et al. studied 36 healthy males who were not
vitamin deficient. They found a positive association
between an increased number of micronuclei and lower
plasma vitamin B12 concentrations, suggesting vitamin
B12 levels are instrumental in maintaining DNA integ-
rity—not just in vitamin B12 deficient population, but also
in a healthy one (Milic et al. 2010). Kapiszewska et al.
demonstrated that more than 400 pg/ml of vitamin B12 in
plasma in subjects with a positive folate balance is critical
for genomic stability, with uracil misincorporation into
DNA being further related to the MTHFR genotype
(Kapiszewska et al. 2005). The level of folate and B12
needed to prevent genome instability is significantly
greater than the level needed to prevent anemia (Table 2).
Variants in one carbon metabolism that induce uracil
accumulation in DNA, defective DNA repair, and chro-
mosome instability, may render folate-deficient cells more
sensitive to the damaging effects of a second external stress
(Ames 2000). This raises particular concerns for astronauts
with methyl cycle defects who are exposed to ionizing
radiation from a variety of sources, including galactic
cosmic rays, solar protons, and high energy electrons and
protons trapped by the Earth’s magnetic field (Van Allen
Belts).
To put this in perspective, it is estimated that, during a
mission to Mars, every cell nucleus in an astronaut’s body
would be hit by a proton or a secondary electron every few
days, and by an HZE particle about once a month (Jain
et al. 2011). Recent data from the Radiation Assessment
Detector (RAD) experiment on the Mars Science Labora-
tory (Zeitlin et al. 2013) reveal that a during a 360-day
Mars transit mission, an astronaut would receive a dose of
about 662 millisieverts (mSv). This is just short of inter-
national space agencies career exposure limits of
1,000 mSv, a limit that corresponds to a 3 % risk of
exposure-induced death from cancer (Kerr 2013). Levels of
exposure for sensitive neural tissue like the hippocampus
are independently set by NASA at 500 mSv per year and
1,500 mSv for a career (Cucinotta et al. 2012).
These exposure data argue for a dedicated effort aimed
at better characterization of all inherent influences on DNA
stability and DNA repair prior to entering such radiation
environments, as well as during such exposure.
This is highlighted by concern about the extent to which
one carbon defects may actually mimic the degree of DNA
damage one might encounter in the space radiation envi-
ronment. For instance, Fenech et al. found that the chro-
mosomal damage in cultured human lymphocytes, caused
by reducing folate concentration from 120 to 12 nmol/l, is
equivalent to that induced by an acute exposure to 0.2 Gy
of low linear-energy-transfer ionizing radiation (e.g.,
X-rays), a dose of radiation that is 10 times greater than the
annual allowed safety limit of exposure for the general
population (Hartwig 2001; Fenech 2010; Fenech and Crott
2002).
Raising additional concern is the potential impact of one
carbon deficits and concomitant exposure to radiation in
space. While this has not been studied in space, Earth-
based ex vivo and in vitro studies are informative. Fenech
et al. studied the combined effect of folic acid deficiency
and radiation exposure on genome stability, using cultured
lymphocytes of 12 human subjects with different MTHFR
genotypes. Ex vivo cells were grown for 9 days, using
different concentrations of folic acid (12, 24, and 120 nM
folic acid), and exposed to 0.5 Gy of gamma rays.
The effect of folic acid was highly significant
(p \ 0.001) and explained[50 % of variance of both types
of micronuclei. Also, nucleoplasmic bridges and buds were
significantly increased under low folate supply. The
increase in bridges was mainly observed in MTHFR 677TT
cells, highlighting a significant effect of the MTHFR
genotype (p \ 0.006) on this biomarker.
Beetstra et al. studied the micronucleus assay in 10-day
WIL2-NS cell cultures at four different folic acid concen-
trations (0.2, 2, 20, and 200 nM) that span the physiolog-
ical range in humans. Folic acid deficiency and c-
irradiation were shown to have a significant interactive
effect on frequency of cells containing micronuclei, with
the frequency of radiation-induced micronucleated cells
increased with decreasing folic acid concentration (Beet-
stra et al. 2005). Exposure to 20 nM folate resulted in
effects similar to those caused by 1.0 Gy of radiation, a
level that is carcinogenic and some 50 times the annual
safe radiation exposure upper limit. While both radiation
and folate deficiency caused DNA breaks, their effect on
gene expression were somewhat divergent. Radiation
activated excision and DNA double-strand break repair
genes, but it repressed mitochondrial genes. Folate defi-
ciency activated base and nucleotide excision repair genes,
but not DNA double strand break repair genes.






Plasma folate (ng/ml) 2.2 21 (7.3–53.0)
RBC folate (ng/ml) 132 313–700
Plasma B12 (pmol/l) 150 400
Beck and Olek (2003), Fenech (2012)
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These studies make a compelling case for how one carbon
dysregulation may trigger DNA effects similar to those seen
in radiation exposure (representing a mutational event) and
how concomitant exposure to space radiation (a convergent
risk for mutational events) represents a set of conditions in
need of attention by the space biomedicine community.
4.3 One carbon metabolism and bone health
Loss of bone integrity is one of the most challenging aspects
of space flight. For example, a group of astronauts who had
spent from 4.3 to 6.5 months aboard the ISS showed an
average loss of 14 % in femoral strength. In some subjects,
the magnitudes of the reductions in proximal femoral
strength were comparable to estimated lifetime losses asso-
ciated with aging (Keyak et al. 2009, Smith and Heer 2002).
The effect of disordered one carbon metabolism on
osteoclast activation, decreased osteoblast activity, and
increased bone fragility renders it a compelling candidate for
addressing this perplexing problem of space flight. Most
evidence points to a dynamic interplay between Hcy (ele-
vated), folic acid, vitamin B12, pyridoxine (decreased)
(Dhonukshe-Rutten et al. 2005), and SNP variants, such as
MTHFR (heterozygotes and homozygotes). In those with the
MTHFR mutation, riboflavin [as a flavin adenine dinucleo-
tide (FAD) cofactor] contributes further to the adverse
effects of one carbon transfer derangement on bone.
In studies of cultured osteoclasts from healthy male
donors (34 ± 5 years), the combined reduction of folate,
B12, and B6 stimulated dentine resorption activity (DRA)
up to 211 %. Reduction of only one of these vitamins
stimulated DRA up to 250 % (folate: maximum increase
248 %, p \ 0.018; B12: maximum increase 252 %,
p \ 0.001, B6: maximum increase 247 %, p \ 0.001). In
addition, Hcy in varying physiologic concentrations (up to
2,500 lmol/l) has been shown to stimulate dentine
resorption up to 395 % (p \ 0.001) (Jain 2009).
These findings are in agreement with human studies
demonstrating a correlation between plasma concentrations
of Hcy and biochemical bone resorption markers (Herr-
mann et al. 2005, 2007). A recent meta-analysis involving
14,863 subjects concluded that elevated Hcy significantly
increases the risk of fracture (Yang et al. 2012).
Riboflavin deficit may confer additional risk to bone fra-
gility, even in the absence of microgravity. For example,
women homozygous for MTHFR 677TT, who were also in the
lowest quartile of riboflavin intake, had a 1.8 (95 % CI
1.1–2.9, p = 0.01) times higher risk for incident osteoporotic
fractures and a 2.6 (95 % CI 1.3–5.1, p = 0.01) times higher
risk for fragility fractures compared with the 677CC genotype
(interaction, p = 0.0002). In the lowest quartile of dietary
riboflavin intake, T-homozygous individuals (men and
women combined) had higher (22.5 %) Hcy levels compared
with C-homozygotes (mean difference = 3.44 mM, p =
0.01; trend, p = 0.02) (Yazdanpanah et al. 2008).
The effect of one carbon derangement on bone in the
astronaut population in space has not been investigated.
Given that declining bone density is among the principal
concerns surrounding humans in space, understanding the
added risk of disordered one carbon metabolism warrants
further attention.
4.4 One carbon metabolism and hypertension
The conditions of increased ICP and intraocular pressure in
space may also be partially linked to one carbon metabo-
lism. Previously, the MTHFR C677T mutation has been
shown to be a risk factor for hypertension in Earth-based
conditions (Kesler et al. 2010). Riboflavin is an important
essential input for those with the MTHFR mutation, since
riboflavin is part of the FAD coenzyme complex that
activates MTHFR. In vitro studies have shown that ther-
molabile MTHFR is *10 times as likely as the wild-type
enzyme to dissociate from its FAD prosthetic group and
thus become inactivated (McNulty et al. 2002).
Wilson et al. examined a population of MTHFR 677TT
homozygotes in 2004, with a follow up in 2008. They
found a graded relation between the T allele and blood
pressure at both time points, with a significantly higher
systolic BP (by 16 mmHg) in patients with the TT genotype
than in those with the CC genotype in 2004—a difference
that remained significantly higher (by 13 mm Hg) in 2008.
When riboflavin was given to TT homozygotes with ele-
vated blood pressure, it produced an overall decrease in
systolic (-9.2 ± 12.8 mmHg; p = 0.001) and diastolic (-
6.0 ± 9.9 mmHg; p = 0.003) blood pressure. To put these
results into an Earth-based context, it would take roughly
10 kg of weight loss or an exercise regimen that burned
4,200 kcal/week to achieve comparable decreases in blood
pressure (Wilson et al. 2012).
Of further interest is the finding that individuals with the
MTHFR mutation may suffer from deficits in spatial navi-
gation. This has been found in MTHFR mutants with
hypertension, which may be a result of the cerebrovascular
changes associated with the variant (Deshmukh et al. 2009).
These findings argue in favor of assessing genotypes,
such as MTHFR, in all astronaut training, with additional
attention to the key essential input (riboflavin) that governs
the MTHFR-FAD enzyme–coenzyme complex.
4.5 One carbon metabolism and personalized
countermeasures
To date, SNP variants in one carbon metabolism have not
been characterized in the astronaut population. Given the
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findings of Zwart et al. regarding metabolites of one carbon
metabolism and ocular disturbances on a subgroup of ISS
astronauts, the influence of one carbon metabolism on
blood pressure, the effect of one carbon metabolism on
bone, the influence of one carbon metabolism on genome
stability, and the potential additive effect of cosmic radi-
ation on unstable DNA, it is evident that this single met-
abolic feature has potential far-reaching impact on humans
in space.
As a further point of reference, our group routinely
applies detailed molecular profiling on an individualized
basis with human subjects entering extreme environments
and in those participating in extreme competitive condi-
tions. For example, we apply the personalized medicine
paradigm to drivers in The 24 Hours of Le Mans racing
event and in the US Le Mans Series (Heyman and Schmidt
et al., unpublished results). With specific reference to
variants in one carbon metabolism, we identified MTHFR
heterozygosity (677CT) in four of six drivers (all of
European heritage), which suggests that variance in one
carbon metabolism may emerge in small subject popula-
tions similar to astronauts.
Fredriksen et al. profiled a large European population of
10,601 subjects for genetic polymorphisms related to one
carbon metabolism. His group confirmed a high penetrance
of both the MTHFR C677T and the A1298C, with only
14 % of subjects possessing the wild type for both SNPs,
while 86 % possessed at least one mutant MTHFR allele.
Fully 17.4 % were heterozygous for both MTHFR
C677T and A1298C (Fredriksen et al. 2007) Table 3.
Under our proposed emergent model of personalized
medicine for human space flight, one can envision that
assessment of one carbon metabolic networks would
become standard protocol for all astronauts. From this pre-
mission assessment, medical teams may develop person-
alized countermeasures for each astronaut, regardless of
where he or she falls on the continuum of these converging
molecular influences.
A hypothetical pre-mission assessment of one carbon
metabolic status is presented in Table 4. Countermea-
sures would be based on the status of individual
biomarkers.
5 Gene variants associated with iron metabolism
on earth and in space
Gene variants contributing to disordered iron metabolism
represent another example of metabolic alterations that
may modify the risk profile of astronauts entering the space
environment. Iron is the most redox-active trace element
found in the human body. Interaction of bodily iron with
gamma or other forms of radiation represents one level of
risk. Exposure to changing oxygen saturation conditions in
habitation versus extravehicular activities (EVA) condi-
tions represents a hypoxia–hyperoxia paradigm, where the
known presence of excess catalytic iron may pose addi-
tional risk. Beyond this, iron represents a potential general
risk across all performance and disease conditions in space
(Smith 2002a).
Iron exerts its primary oxidative effects via the Haber–
Weiss and the Fenton reaction, producing highly reactive
hydroxyl radical species. The Haber–Weiss reaction gen-
erates hydroxyl radical (OH) from hydrogen peroxide
(H2O2) and superoxide (O2-).
The first step involves reduction of ferric ion to ferrous
iron. Hydroxyl radicals formed from the Fenton reaction
are strongly reactive with DNA, lipids, proteins, and a
range of other biomolecules.
The Haber–Weiss reaction:
Fe3? ? O2- ? Fe2? ? O2
The second step is the Fenton reaction:
Fe2? ? H2O2 ? Fe3
? ? OH- ? OH
Net reaction:
O2- ? H2O2 ? OH ? OH- ? O2















Nuclear buds MTR (A2756G)




Total nuclear uracil CBS (C699T) Pyridoxine
TCN2 (C776G) Riboflavin
Assessment of the aggregate influences outlined in Table 4 would
allow strategic preparation and countermeasure development for each
individual, based on his particular genotype and metabotype, thus
addressing, to the greatest degree possible, his molecular variances
MTHFR methylenetetrahydrofolate reductase, MTR methionine syn-
thase, MTRR methionine synthase reductase, BHMT betaine Hcy
methyltransferase, CBS cystathionine b-synthase, TCN2 transcobal-
amin II (Adapted from Leopardi et al. 2006)
Table 3 Number of genotype combinations of polymorphisms in the




1298AA 1,492 2,217 783
1298AC 2,469 1,848 16
1298CC 1,246 43 0
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The unique role of iron as a potential risk factor in
human space flight is highlighted by the high prevalence of
the genetic variant for hemochromatosis (HFE). HFE is
among the most common genetic variants in humans, with
two common missense mutants: C282Y and H63D. Among
Caucasians, one in 200–250 are homozygous for C282Y
(Adams et al. 2005). The highest reported C282Y homo-
zygosity was reported in Ireland (1/83) (Gleeson et al.
2004). In Caucasians, one in 50 are compound heterozy-
gotes (one H63D and one C282Y mutant allele). As many
as one in 8 to 10 are simple heterozygotes (carrier of one
C282Y mutation).
In *60–90 % of cases of HFE mutations, a missense
mutation occurs at base 282, which causes tyrosine to be
substituted for cysteine (C282Y). The tyrosine substitution
results in dysregulation of transferrin-mediated uptake of
iron in the gut. This leads to excess iron deposition in cells
throughout the body, including but not limited to liver,
heart, eyes, brain, joints, and pancreas (Jahanshad et al.
2012). While normal transferrin saturation is 45–55 %,
saturation levels can rise to 65–85 % in those with this
mutation. Normal serum ferritin levels are 50 ng/ml in wild
type HFE homozygotes and may rise above 600 ng/ml in
HFE mutant homozygotes.
5.1 HFE, oxidative stress, and genome instability
The elevated iron burden encountered in HFE mutants has
been shown to increase formation of 8-iso-PGF2a (a fin-
gerprint of fatty acid oxidation) in Earth environments.
Twenty-one patients with HFE (C282Y) were compared
with 21 matched controls to determine whether HFE-rela-
ted HFE was associated with increased oxidative stress.
Isoprostane levels in HFE subjects were determined to
be 245 pg/mg creatinine (interquartile range 157–348)
when compared with controls at 128 pg/mg creatinine
(interquartile range 106–191; p = 0.002). After phlebot-
omy treatment and normalization of the iron parameters in
the HFE group, 8-iso-PGF2a urinary excretion was low-
ered to control levels [146 (117–198) pg/mg creatinine,
p = 0.38 vs. controls] (Kom et al. 2006).
Genetic material is uniquely susceptible to oxidative
stress triggered by iron exposure. Common markers of
nuclear RNA damage include 8-oxo-7,8-dihydroguanosine
(8-oxoGuo), and related 20-deoxyribonucleoside and ribo-
nucleoside. In a study of newly diagnosed HFE patients,
baseline 8-oxoGuo (RNA oxidation) was increased 2.5-fold
over controls. Following phlebotomy (until serum ferritin
was below 30 lg/l), 8-oxoGuo excretion returned to values
similar to controls. Excretion of the DNA product 8-oxo-
7,8-dihydro-20-deoxyguanosine was reduced by 30 % fol-
lowing phlebotomy (Broedbaek et al. 2009).
This latter study demonstrates that oxidative stress is an
important feature of the iron overload seen in hereditary
HFE, which results in RNA oxidation that is reversible
upon phlebotomy and strongly correlated with serum fer-
ritin levels. Elevated iron and attendant elevation of 8-oxo-
7,8-dihydro-20-deoxyguanosine have also been linked with
significant decreases in bone mineral density in the total
hip, trochanter, femoral neck, and pelvis after space flight.
(Zwart et al. 2013).
These oxidative changes associated with the HFE
genotype may have cardiac implications for the asymp-
tomatic subject. A recent study sought to examine the
relationship between left ventricular diastolic function
measured with tissue Doppler strain rate (SR; a sensitive
echocardiography-derived measure of diastolic function),
and oxidative stress in asymptomatic HFE subjects and
control normal subjects (age 30–74). In the HFE subjects
(confirmed C282Y homozygosity), the SR demonstrated
moderate, but significant correlations with biomarkers of
oxidative stress, with no correlations noted in normal
subjects (Shizukuda et al. 2009).
Taken as a whole, the data suggest that the iron overload
that accompanies HFE variants may contribute substan-
tially to increased oxidative stress. Increased oxidative
damage to nuclear material may have significant implica-
tions for the affected humans inhabiting space. The
potential effect on cardiac function raises additional com-
pelling reasons for understanding the genetic profile of
space flight candidates (Hallgren and Sourander 1958;
Nandar and Connor 2011). The convergent impact of
radiation (gamma, proton and HZE particles, etc.) and iron
on oxidized nucleic acids has not been studied to our
knowledge.
5.2 Hypoxia–hyperoxia paradigms associated
with disordered iron metabolism
The finding of increased oxidative stress associated with
HFE in Earthbound environments raises additional con-
cerns when coupled with the unusual atmospheric condi-
tions encountered in space flight. While iron is highly
reactive under normal circumstances, the oxidative capac-
ity of iron in the presence of high oxygen tension or
oscillating oxygen levels in space has not been extensively
studied. This is precisely the condition that will be
encountered by astronauts engaged in prolonged missions
BLEO to the Moon, Near Earth Objects, and Mars, because
of the highly variable oxygen conditions deployed under
the oxygenation and pressurization criteria outlined by
current design reference missions (DRMs).
These DRMs result in conditions during EVAs, and in
the exploration and habitat environments, that will expose
astronauts to oscillations between alveolar hyperoxia
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(133 mmHg PAO2) and alveolar hypoxia (83 mmHg
PAO2), respectively. Furthermore, oscillating arterial O2
(128 and 78 PaO2 mmHg) concentrations may be even
more deleterious to the crew in light of the degradation in
visual acuity data accumulated to date (Mader et al. 2011;
Scheuring et al. 2007) (Table 5).
The space suit used for EVAs will be a low pressure suit
at *4.3 psi and 90–100 % O2. Operations in the transit
exploration environment are planned to be carried out at
7.6–8.2 psi and 34 % O2 in the habitat and multi-mission
space exploration vehicle (MMSEV), and at 10.2 psi and
26.5 % O2 in the multipurpose crew vehicle (MPCV)
(Conkin and Wessel 2008, 2009, Conkin 2011). DRMs for
exploration environments in the next generation of U.S.
space vehicles and habitats are summarized in Fig. 5.
The scientific literature reveals several potential prob-
lems with not only hypoxia (8.2/34), but also with hyper-
oxia (85–100 % O2). In combination, especially in an
oscillating mode where hypoxia and hyperoxia are
exchanged every 48 h during EVA/IVAs (Fig. 5), the PiO2,
PAO2, and PaO2 values represent unknown risks under the
proposed DRM scenarios.
No space exploration or habitation analogue study has
yet employed this hypoxia–hyperoxia regimen. Thus, the
only baseline data obtained derive from studies conducted
on single events alone (i.e. hyperoxia or hypoxia) (Bit-
terman 2009), with these studies yielding data that indicate
degenerative effects on the retina at high 90–100 % O2
concentrations (Xu et al. 2010). Combining significant
delta O2 (hyperoxia/hypoxia) concentrations and pressures,
which cause the retina to experience varying O2 concen-
trations, with the already problematic visual detriment
effect, could lead to even greater visual acuity and recovery
difficulties. This is anticipated to be accentuated during
long duration missions, as high concentrations of O2 have
been shown to be toxic in their own right.
Adding excessive total body iron to this hypoxia–
hyperoxia paradigm has not been studied. However, the
known high reactivity of iron in an oxygen-rich environ-
ment is expected to add an additional level of risk to those
astronauts either heterozygous or homozygous for HFE,
who have not had their iron status properly regulated. This
is especially true for oxidant-sensitive tissues. For instance,
it is known that HFE is associated not only with excessive
accumulation of free iron in the retina and retinal pig-
mented epithelium, but also with excessive accumulation
of heme. Since heme is toxic at high levels, as is free iron,
heme-induced oxidative damage may also play a role in
HFE-associated retinal pathology (Gnana-Prakasam et al.
2011).
In space, there is an additional stressor that may interact
with the high iron genotype and the hypoxia–hyperoxia
paradigm. This is high energy particle radiation (primarily
proton energy in Low Earth Orbit and galactic cosmic
radiation in BLEO), which has been extensively studied
with regard to its impact on the lens (Cucinotta et al. 2001;
Rabin et al. 2005; Jones et al. 2007). The scarce evidence
on the effects of space flight on the retina is limited to a
very few experiments on rats which showed retinal cell
death due to high energy-particle radiation (Philpott et al.
1978, 1980). One recent project aboard the ISS (ALTEA)
has been addressing functional effects of microgravity and
cosmic radiation, most often reflected as abnormal visual
perception (‘‘light flashes’’) (Narici et al. 2004). Combining
hypoxia and hyperoxia with increased radiation exposure
in the range that will be experienced by space travel and
habitation BLEO has been recently shown to have pro-
nounced and negative synergistic effects (Pietrofesa et al.
2013; NASA LSDA database 2013).
Space medicine physicians will be asked to mitigate the
risk associated with the combinatorial events of reduced
gravity, hypoxia–hyperoxia, and radiation. Understanding
Table 5 Nominal oxygen partial pressures in next generation spacecraft and environments
Environment PB FIO2 (mmHg) pO2 (mmHg) PIO2 (mmHg) PAO2 (mmHg) PaO2 (mmHg)
(psi) (mmHg)
MPCV 10.2 527 0.265 139 127 82 77
MMSEV 8.2 414 0.34 132 117 83 78
HABITAT 7.6 393 0.32 125 111 66 61
SUIT 4.3 222 1.0 222 175 133 128
Earth, Sea level 14.7 760 0.21 159 150 104 99
Comparative total pressures (PB), oxygen fractions (FIO2) and partial pressures of oxygen at various stages in the different environments of the
Exploration vehicles (Courtesy of Dr. Johnny Conkin, NASA/USRA)
pO2 is ambient oxygen partial pressure; PB 9 FIO2; FiO2 is the oxygen fraction; PB is the total pressure; PIO2 is inspired oxygen partial pressure;
(PB-47) 9 FIO2; PAO2 is alveolar oxygen partial pressure; (PB-47) 9 FIO2 - PACO2 9 (FIO2 ? [(1-FIO2)/RER)], where PACO2 is
40 mmHg and RER is 0.85; PaO2 is arterial oxygen partial pressure; PaO2 = PAO2 - 5 for the contribution of venous mixture
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astronaut status with regard to body burden of catalytic
metals, such as iron, should become a central component of
this aspect of risk management.
5.3 Iron metabolism in space flight
Iron metabolism in space flight is substantially different than
on Earth, due to a host of physiologic anomalies peculiar to
reduced gravity environments. Figure 6a and b illustrate
many of the conditions experienced by humans on Earth,
with similar conditions seen in astronauts in flight. Specifi-
cally relevant are changes in the health of the eyes, vessels,
heart, lung, bone, immune system, and various organs.
Smith et al. have shown that iron metabolism is altered
in astronaut populations, which is partially related to the
food system and space conditions. In one space flight
study, crew members consumed a mean of only 80 % of
their recommended energy intake. On landing day, their
body weight was less (p = 0.051) than before flight. This
was associated with increased serum ferritin (p \ 0.05),
along with decreased ferritin saturation and hematocrit.
Other acute-phase proteins were unchanged after flight,
suggesting that the changes in iron metabolism are not
likely to be solely a result of an inflammatory response.
Collectively, these data suggest that storage pools of iron
may be altered in the microgravity environment (Smith
2002a). Genotype was not profiled in these astronauts, but
HFE heterozygosity or homozygosity would be expected to
confer an additive risk of unknown proportion.
Also in this study, urinary 8-hydroxy-20-deoxyguanosine
concentration was greater, suggesting DNA damage was
greater after the flight. RBC superoxide dismutase was less
after flight (p \ 0.05), further indicating increased oxida-
tive damage. Despite vitamin D supplementation during
flight, serum 25-hydroxycholecalciferol was decreased
after flight (p \ 0.01). Bone resorption was increased after
flight, as indicated by several markers. Bone formation,
assessed by several markers, did not consistently rise 1 day
after landing. These data provide evidence that bone loss,
altered vitamin D status, and oxidative damage are among
critical nutritional concerns for long-duration space trav-
elers. (Smith et al. 2001, 2005a, b).
5.4 HFE and personalized countermeasures
To date, HFE genotypes have not been characterized in the
astronaut population. Applying the personalized medicine
paradigm, one can envision two hypothetical astronauts
preparing to enter the space environment, each with dis-
tinctly different profiles with regard to iron status
(Tables 6, 7). One is an astronaut with a normal (or wild
type) HFE profile. She is a 35-year-old menstruating
female, who loses blood (and iron) regularly as a result of
menses. Her transferrin saturation is 45 % and her serum
ferritin is 50 ng/ml (lg/l). Her mission team member is a
55 year old male astronaut who is homozygous (possesses
two mutant alleles) for HFE. His transferrin saturation is
75 % and his serum ferritin is 600 ng/ml.
At first glance, it is evident that the iron burden on the
male astronaut is considerably greater than his female
cohort. He is entering the high radiation space environment
and cyclic hypoxia–hyperoxia conditions with a body
burdened by high levels of a redox-active transition metal
(Fe). We assert that this poses a unique risk that requires
countermeasures tailored to his particular needs.
Under this scenario, the female astronaut will be pre-
scribed a normal diet with regard to iron, while being sup-
plemented with iron at a typical dose of 18 mg/day. The male
will be prescribed a heme–iron-restricted diet with no iron
supplementation. In addition, he should undergo a series of
Fig. 5 Cyclical variations in PaO2 and PAO2 in a typical habitat to
EVA condition. A likely DRM: MMSEV at mild hypoxia for 16 of
24 h, then 8–10 h of EVA at hyperoxia. The EVA cycle would be
every 48 h for any given astronaut, so it would be MMSEV 16 then
8–10 EVA; then 24 MMSEV, then 8–10 EVA and 16 MMSEV; then
24 MMSEV; then 8–10 EVA and 16 MMSEV. Then 48–72 h
weekend off at Habitat/or MMSEV atmospheric conditions
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pre-mission phlebotomy treatments for a period of several
months, until his serum ferritin is lowered to *50–100 ng/
ml (the exact target of which the aerospace medical com-
munity should address by some consensus). For extended
missions, a policy will have to be developed to monitor and
manage serum iron while in space craft or in habitats.
In this section, we explored the impact of selected geno-
types on potential aspects of astronaut health and perfor-
mance by citing only three categorical examples involving
SNPs of relatively high penetrance, involving: (1) drug
metabolism, (2) one carbon metabolism, and (3) iron regu-
lation. It is important to note that some 3–10 million SNPs
exist in the human genome (Human Genome Project Data-
base). The space biomedicine field employing personalized
medicine will be expected to narrow this list to those SNPs
with the greatest relevance to humans entering the uniquely
extreme environment of space. Those SNPs associated with
the following phenotypes would be considered among those
of initial import including, but not limited to, (1) drug
responsiveness, (2) disease susceptibility, (3) performance
deterioration, (4) physical tolerance, (5) psychological tol-
erance, (6) muscle metabolism, and (7) bone metabolism.
Thought leaders in the field of personalized medicine and
human space flight will have to consider those likely to be
most responsive to countermeasures.
6 Small molecules, essential inputs, DNA repair,
and metabolic networks on earth and in space
In the previous section, we described three examples of
genetic variants in a manner that represents a novel way of
Table 6 Hypothetical personalized countermeasures based on genotype and metabotype
Gender HFE Genotype
(C282Y or H63D)
Serum ferritin Transferrin saturation Iron in food
Iron supplementation
Female: 35 year old Wild type (normal) 50 ng/ml 45 % Iron in food permitted
Yes, 18 mg/day suppl
Male: 55 year old Homozygous (HFE) 600 ng/ml 75 % Dietary iron restriction
No iron supplementation
Employ pre-mission phlebotomy to
target serum ferritin at 50–100 ng/ml
Monitor serum ferritin on long missions
Table 7 Suggested pre-mission iron assessment
Single nucleotide polymorphisms Serum markers of iron status
HFE (C282Y), HFE (H63D) Serum iron
Serum ferritin
Transferrin saturation
Total iron binding capacity
Fig. 6 (a) Adapted from the National Institute of Standards and Technology; (b) Courtesy of NASA Outreach and Education
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looking at individual astronaut susceptibility, risk, and
countermeasure development. In each case of the cited
examples, there are key small molecules (or elements) that
strongly modify the effect these gene variants will likely
have on the human response in space. We collectively refer
to these small molecules and elements as essential inputs.
Essential inputs refers collectively to the class of small
molecules, amino acids, vitamins, fatty acids, and trace
elements that must be obtained from the diet. They cannot
be synthesized by the human body. This also includes
conditionally essential inputs that may become essential, as
a result of genotype, drug therapeutics, environmental
conditions, or dietary deficiencies of essential precursors.
They are collectively referred to as inputs, because these
are external components that input into the system to col-
lectively influence all metabolic activities in humans.
These effects can be pronounced, regardless of the geno-
type of the individual.
It is tempting to view these micronutrient essential
inputs only in general ways and to underestimate the
impact of relative states of insufficiency. However, if one
gives the requisite attention to the core metabolic steps in
which these elements participate, the true magnitude of
small deficits in these inputs can be appreciated.
As a point of reference, a flavin-containing cofactor,
FAD or FMN (riboflavin-derived), is utilized by 151 (4 %)
of the 3,870 enzymes catalogued in the ENZYME data-
base. Pyridoxal-5-phosphate (vitamin B6) is utilized by
112 (3 %) of the 3,870 enzymes catalogued in the
ENZYME database (Ames et al. 2002).
Niacin is involved in over 400 NAD(P)-dependent
reactions, giving it the potential to influence every area of
metabolism, including genomic stability, impaired cell
cycle arrest and apoptosis, delayed DNA excision repair,
accumulation of single and double strand breaks, chro-
mosomal breakage, and telomere erosion (Kirkland 2012).
The role of nicotinamide (niacin) in DNA repair and
maintenance of genomic stability is tightly related to its
functions as an NAD ? precursor and a substrate for
PARP-1. PARP- 1 is a nuclear enzyme that detects DNA
damage, binds to DNA single or double strand breaks, and
then uses NAD ? as a substrate to form nicotinamide and
ADPribose (Surjana et al. 2010).
Zinc is a component of more than 3,000 zinc-associated
transcription factors, including DNA-binding proteins with
zinc fingers, and more than 300 enzymes, including several
proteins involved in DNA transcription, regulation, and
repair (e.g. DNA polymerase). For instance, PARP-1 has
two zinc-fingers that bind to DNA strand breaks, causing
catalytic activation, which leads to NAD? consumption
and poly (ADP-ribose) formation (Kirkland 2012). Zinc
also plays an important role in protecting DNA from
damage, as part of antioxidant complexes, such as Cu/Zn-
superoxide dismutase. DNA base excision repair is a major
pathway responsible for the repair of both cellular alkyl-
ation and oxidative DNA damage. One critical step in this
pathway involves the cleavage of damaged sites in DNA by
apyrimidic endonuclease (APE), an important endonucle-
ase in base excision repair. Low cellular zinc increases the
expression of (APE), most likely in response to DNA
damage induced by low zinc (Ho 2004).
Selenium is involved in a smaller total number of enzyme
systems. However its influence is vast. For instance, three
different selenium-dependent iodothyronine deiodinases
(types I, II, and III) can both activate and inactivate thyroid
hormone, by acting on T3, T4, or other thyroid hormone
metabolites (Bianco and Larsen 2006). Selenium may also be
protective by preventing DNA damage from occurring, by
increasing the activity of repair enzymes, such as DNA
glycosylases and DNA damage repair pathways that involve
p53, BRCA1, and Gadd45 (Bera et al. 2013).
Varying, but similar ‘‘participation numbers’’ for a wide
range of elements and small molecules can be observed for
over 30 essential inputs, affecting molecular dynamics
across almost all metabolic networks. Individually, deficits
in one essential input have potentially significant effects on
metabolic network regulation in humans in space. When
deficits of multiple essential inputs converge, the effect on
metabolic networks can be expected to be amplified.
6.1 Essential inputs: magnesium (Mg), DNA repair,
and ATP regulation in space
Mg is an appropriate example of an essential input by
virtue of its participation in some 300 separate enzyme
systems. The relevance of Mg is further highlighted by
recent findings from the ISS, in which urinary Mg levels
were found to be 44 % lower after landing than before
launch (p \ 0.001). Specifically, 55 % of ISS crew mem-
bers had Mg concentrations lower than the low end of the
clinical range (3.0 mmol/day) (Smith et al. 2005a, b). After
6 months in space, there is a loss of Mg reservoirs, with
35 % loss in some leg muscles (Fitts et al. 2010) and up to
2 % bone loss per month (Rowe 2010).
6.2 Mg and DNA repair
Mg is an essential cofactor in almost all enzymatic systems
involved in DNA processing, with a stabilizing effect on
DNA and chromatin structure (Hartwig 2001). At its core,
Mg cations bind to DNA and reduce the negative charge
density, thereby stabilizing the structure of DNA (Anas-
tassopoulou and Theophanides 2002). Mg is an essential
cofactor for enzyme systems involving DNA repair, such
as mismatch repair (MMR), base excision repair, and
nucleotide excision repair (Hartwig 2001).
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DNA MMR is responsible for the recognition and repair
of mispaired bases and small insertion–deletion loops that
are formed during DNA replication or recombination
between non-identical DNA sequences. MMR activity
lowers the mutation frequency in the genome by 2–3 orders
of magnitude, with a loss of function of one of the MMR
proteins resulting in a mutator phenotype. Mg influences
switching in MutS (mismatch recognition enzyme) by
inducing faster and tighter ATP binding, allowing rapid
downstream responses. Mg is also essential for double-
strand break repair, such as that encountered in one carbon
deficits noted previously (Nishino and Morikawa 2002).
Mg status may have significant ramifications for astro-
nauts entering conditions where demands on DNA repair
are increased through radiation exposure and oxidative
stress. For instance, low dietary Mg intake has been asso-
ciated with poorer DNA repair capacity and increased risk
of some cancers. In joint effects analyses, compared with
those with high dietary Mg intake and proficient DNA
repair capacity (DRC), the OR (95 % CI) for lung cancer in
the presence of both low dietary Mg and suboptimal DRC
was 2.36 (1.83–3.04) (Mahabir et al. 2008).
6.3 Mg and energy metabolism
Maintaining adequate or optimal Mg status in the space
environment may also be necessary to optimize work
capacity and regulate oxygen utilization. This is based on
the central role of Mg in energy metabolism. For instance,
roughly one-third of all intracellular Mg is found within
mitochondria. Mg bound to ATP is the sole biologically
active form of ATP found in humans (wherein Mg is bound
to the phosphate groups of ADP and ATP, as MgATP2-).
Moreover, Mg is a central ion in ATP synthase, binding to
phosphate in the catalytic F1 moiety of ATP synthase.
Also, Mg is required for a series of enzymes involved in
glycolysis (Table 8), adding further to Mg’s central role in
energy metabolism.
Depletion–repletion studies involving Mg demonstrate
that efficiency of oxygen utilization may be substantially
altered during Mg depletion. Specifically, when Mg levels
were low (112 mg/day), the total amount of oxygen
required for a given amount of work was increased. When
Mg levels were raised (312 mg/day), the same amount of
work required less oxygen (Lukaski and Nielsen 2002).
These findings correlated with increased RBC and muscle
Mg (replete) and decreased RBC and muscle Mg (deple-
tion) (Fig. 7). While this has potential implications for
astronaut safety and performance, it may also have impli-
cations for engineering related to oxygen provision in
habitats or within space suits.
If the effects of Mg on VO2 persist in the space envi-
ronment, one must view the declining Mg status
encountered with mission duration in a new light. If Mg
status declines with mission duration, especially on the
very long duration missions envisioned for Mars, then there
is a hypothetical impact of mission duration on VO2 max,
energy efficiency, and potentially also on DNA stability.
7 Omics technology approaches: combinatorial
influences complicate strategies for countermeasure
development
The need for a systems biology approach to develop per-
sonalized medicine programs for astronauts derives from
two key convergent influences. First, there are vast
molecular networks that interact dynamically to influence
astronaut susceptibility to any specific environment or
condition to which he or she is exposed. Second, there are a
series of mission stressors that impact heavily upon the
individual susceptibility of each astronaut. Whether one
thrives within the space environment may be heavily
dependent upon individual susceptibility, space environ-
mental exposures, and whether the countermeasures
deployed for an individual astronaut are sufficient to
overcome these susceptibilities. By illustration, one can use
DNA stability to explore these convergent influences.
7.1 Convergent effects of essential input deficits
on DNA in space flight
DNA stability and DNA damage are among the key safety
considerations in human space flight. Thus, we will use
DNA stability here to establish a further premise that
concomitant genetic variants and essential input deficits
can aggregate to raise the risk of developing unstable DNA.
On one hand, we have summarized data showing that one
carbon deficits can lead to uracil accumulation in the
nucleus, which may be followed by single- and double-
strand DNA breaks. This alone represents a novel, but
modifiable risk to DNA damage in space.
A further influence described herein is that of iron
excess, which is associated with a common single nucle-
otide polymorphism (HFE). As noted previously, elevated
iron can lead to the oxidation of DNA and RNA, adding yet
another potential convergent variable to the space flight
equation. A separate influence described herein is that of
Mg, which is central to the activity of a wide range of DNA
repair enzymes (base excision repair, MMR, etc.). As noted
above, insufficient Mg has been associated with inefficient
DNA repair, representing another novel, but modifiable
risk to DNA instability in space.
One can quickly see the risk of a single gene variant or
essential input deficit on DNA stability. The aggregation of
two or more variants or essential input deficits represents
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an additional risk, which has not been properly character-
ized in astronauts. Under the limited scenario just descri-
bed, one can envision a condition where altered one carbon
metabolism (due to genetic variant and/or micronutrient
deficit) leads to unstable DNA and DNA strand breaks,
while a convergent deficit (Mg) leads to a reduced effi-
ciency to repair such damage.
The phenomenon of two or more essential input deficits
is plausible, given that one carbon deficits, declining Mg
status, and altered iron metabolism have already been
shown to exist within the flying astronaut population. But it
also illustrates a greater premise asserted within this
review. That is, there is a need to more broadly profile
genotype, essential inputs, and metabolic networks in all
astronauts, so as to begin to identify ‘‘off-target’’ influences
that may bear upon individual susceptibility to the space
environmental condition. This necessarily leads us to
Omics approaches, which allow us to address the requisite
complexity encountered in such analyses.
7.2 Translational Omics strategy for space
The purpose of applying broad analytics and personalized
medicine in human space flight participants is not to reduce
participation or to find biomarkers that will limit the ability
of astronauts to participate in missions. The focus of per-
sonalized medicine in human space flight is to develop
countermeasures that are individualized to each space
participant. The goal of this individualized approach is
aimed at improving all aspects of mission performance, as
well as limiting adverse sequelae of prolonged space flight.
The emergent participation of space tourists will add yet
another layer of complexity that can be addressed by
personalization.
In this review, we primarily highlighted four areas of
biological variance that are fundamental to a personalized
medicine paradigm in human space flight. These include:
(1) gene and small molecule variants associated with
metabolism of therapeutic drugs used in space; (2) gene
and small molecule variants associated with one carbon
metabolism; (3) gene and small molecule variants associ-
ated with iron metabolism and oxidative stress; and (4) Mg
as an essential input with effects on DNA stability and
energy.
We have drawn attention to these areas for the purpose
of simplicity. In practice, the same premise described in
this review can be applied across a wide range of molecular
processes. We suggest here that the more broadly we
understand this variability of molecular networks in each
Table 8 Magnesium effects across metabolic networks
Enzyme Pathway Function
Hexokinase Glycolysis Glucose to glucose-6-phosphate
Phosphofructokinase Glycolysis Fructose-6-phosphate to F-1,6-bisphosphate
Phosphoglycerate Kinase Glycolysis 1,3-Bisphosphoglycerate to 3-phosphoglycerate
Enolase Glycolysis 2-Phosphoglycerate to phosphoenolpyruvate (PEP)
Pyruvate kinase Glycolysis PEP to enolpyruvate
Isocitrate dehydrogenase TCA cycle Isocitrate to a-ketoglutarate
Phosphoenolpyruvate
carboxykinase
TCA cycle Oxaloacetate to PEP
ATP synthase Electron transport chain Magnesium plays a pivotal role in formation of the
transition state where ATP is synthesized from ADP and inorganic phosphate
ATP stability All ATP reactions Mg-ATP is the physiologically active form of ATP
Magnesium is involved in metabolic pathways across vast networks, such as glycolysis, the citric acid cycle, and ATP regulation. Genomics,





















Fig. 7 Oxygen use during Mg depletion and repletion. During Mg
depletion, the amount of oxygen required to do a given amount of
work is increased, thus reflecting decreased aerobic capacity
efficiency during Mg deficiency. Values for Total VO2 and cumu-
lative net oxygen uptake were consistent with these conclusions
derived for VO2 peak values (adapted from Lukaski and Nielsen
2002)
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astronaut, the better we will be able to develop counter-
measures that optimize astronaut safety and performance.
This variability can be assessed by the application of
Omics approaches to space medicine research (Table 9).
For example, one can use Omics to better characterize the
molecular events associated with the variable oxygen
conditions that will be encountered in the space suit EVA
condition compared with the space habitat environment
noted previously (Figure 5). This can be done by using
genomics (SNP profiling) to examine how genotype may
be linked to tolerance in the two conditions. Transcripto-
mics, proteomics, and metabolomics can be used to further
characterize the changing molecular dynamics that might
be associated with the varying PAO2/PaO2/CO2 conditions.
Patterns derived from these research-based Omics
methods, can then be used to identify novel and relevant
biomarkers, which may subsequently be used to develop
personalized countermeasures applied to the individual
astronaut entering such variable oxygen conditions
(Table 10)
Introducing Omics into space biomedicine research adds
a layer of complexity that will initially offer challenges in
technology and methodology. But the ability to identify
novel patterns, novel solutions, and predictive capability is
expected to ultimately reduce complexity, by refining our
engineering designs and human countermeasure
approaches.
7.3 Omics technology approaches to human space
flight countermeasures
Earth-based human space flight research will benefit from
the same range of technologies applied in all domains of
systems biology. This includes, but is not limited to, LC–
MS, GC–MS, NMR, ELISA, electrophoresis, PCR, gene
arrays, protein arrays, flow cytometry, microscopy, and
many others. These technologies will support assessment
of genome, transcriptome, proteome, and metabolome in:
(1) Earth-based space analogue research, (2) short-duration
flight research where specimens are retained for ground
analysis, (3) in-habitat research (such as the ISS) where
retained specimens are returned to Earth for analysis, and
(4) post-mission research.
These technologies can serve the purposes of human
space flight research today, as well as providing the kind of
analytics from which personalized countermeasures can be
developed. However, real time Omics assessment during
space flight and habitation presents a unique set of chal-
lenges, due to vehicle size, instrument weight, fluid han-
dling characteristics in microgravity, and power
constraints.
None of the current analytical technologies or methods
is presently used by any space program to survey the
changing molecular dynamics of astronauts in space.
Instead, samples (blood, urine, or saliva) are frozen at
-80 C in the ISS (MELFI Rack freezers) and usually
(every 90–180 days, notwithstanding schedule changes)
transported to Earth for retrospective analyses, using some
of the aforementioned technologies. Transport volumes are
low, since the returning vehicles, such as the SpaceX
Dragon and Soyuz vehicles, have limited cargo capacity,
when compared with the retired Space Shuttle. Thus,
multiple trips are required to transport MELFI freezer
volumes to the ground.
Table 9 Proposed use of Omics in human space research
Analogues Pre-flight In-flight Habitation Post-flight
Genome (targeted, non-targeted) Yes Yes Yes Yes Yes
Transcriptome (targeted, non-targeted) Yes Yes Yes Yes Yes
Proteome (targeted) Yes Yes Yes Yes Yes
Metabolome (targeted, non-targeted) Yes Yes Yes Yes Yes
Targeted and non-targeted Omics can be used as research tools in any space-related condition for the purpose of understanding human biological
variance associated with space flight or space flight analogue conditions. These methods can be used to generate new hypotheses, serve as a basis
for subsequent targeted analyses, and to identify appropriate molecular targets for subsequent use in developing personalized countermeasures.
Note: The above also includes the trace element pool (sometimes called the metallome)








Genome (targeted) Yes No No No
Proteome (targeted) Yes Yes Yes Yes
Metabolome
(targeted)
Yes Yes Yes Yes
Targeted Omics consists of assessing pre-selected molecular markers.
These biomarkers can be used to identify individual patterns that
space medicine physicians will use in developing personalized
countermeasures. A subset of selected biomarkers may warrant in-
flight or in-habitat measurement, to assure that status for a particular
mission objective is maintained or that specific safety thresholds are
not exceeded. Note: The above also includes the trace element pool
(sometimes called the metallome)
1152 M. A. Schmidt, T. J. Goodwin
123
This impacts research, as well as real-time assessment of
markers relevant to astronaut health and safety. To further
complicate the situation, exploration class missions beyond
LEO to Moon and Mars will be constrained by cost and use
smaller vehicle volumes than the *400 m3 of habitable
volume of the ISS (Wikipedia ISS and assembly pages;
NASA Facts and Figs 2012). The smaller vehicles present
two significant challenges to biochemical analyses. First,
the vehicles will be roughly \ 50 m3 in total volume,
significantly limiting the potential size of the analytical
equipment. Second, this reduced volume eliminates the
ability to use the size- and power-hungry electrical sys-
tems, like the ISS MELFI freezers. This reduces the ability
to store large amounts of samples for later analyses upon
return to Earth.
Future in-flight and in-habitat analytical systems will
require compact analytical solutions to transmit data to
Earth, allowing for monitoring and intervention. The most
likely and reasonable approaches to real time monitoring in
these exploration vehicles will be, at least initially, pro-
teomics-based, compact (small foot print) analytical
equipment capable of operating at low power. It will also
require reagents that, for the most part, show a tolerance to
the environmental conditions in space, in particular radia-
tion. Most of the current systems are fluid- and antibody-
based, and the cartridges require refrigeration.
As with freezers, refrigerators for space vehicles (e.g.
Merlin) provide *20 l of storage in *2 ft3 of volume at a
maximum cold point of -20 C (NASA Fact Sheet). Both of
these requirements are unsuitable for exploration missions
for the reasons outlined above. To combat the inherent fra-
gility of antibodies in hostile conditions, new, more adapt-
able molecules are being used with considerable success.
We and our colleagues are pursuing X-Aptamer tech-
nology for the purpose of assessing a targeted proteome
and metabolome on missions to the Moon and Mars. This
will afford the ability to make real-time assessment of
astronaut health during missions BLEO. X-Aptamers are
small DNA fragments (oligonucleotides) resistant to
denaturation. Like antibodies, they are made to specific
protein epitopes, thus allowing a direct rather than indirect
measure of the biomarker. Real-time evaluation affords
protection of volatile analytes that might otherwise be
degraded. X-Aptamers are coupled with a variety of
chromophores, and have proven to be more tolerant to
hostile environmental conditions and also to have sensi-
tivity comparable to or greater than antibodies (Durland
et al. 1991; He et al. 2012; Hecht et al. 2010).
With these attributes, aptamer reagents may be stored
for years, rather than weeks, without refrigeration and yet
assure reliability when needed. X-Aptamers can be
designed to detect specific proteins as standard antibodies
traditionally do. These can be measured during long-
duration missions and results transmitted electronically to
Earth for medical evaluation. Similar technologies will
have to be developed with careful attention to parameters
of instrument volume, reagent volume, reagent stability to
radiation and temperature, and reliability in microgravity.
In general, the Omics technologies available today are
fully ready to support development of personalized medi-
cine in human space flight. Understanding the real-time
molecular dynamics in long-duration missions will, how-
ever, require significant advances in the field, with regard
to the space flight hardware. There is little doubt that these
advances would also confer considerable value to the
evolution of Earth-based technology and medicine.
7.4 Systematic application of personalized medicine
The application of personalized medicine in human space
flight seems inevitable given the vast pool of knowledge
emerging from the field of systems biology and our
growing understanding of individual susceptibility. Work-
ing from this assumption, it is imperative that a road map
be developed that accounts for the present state of
knowledge, as well as for the evolution of the field going
forward. We suggest that a road map be developed with the
goal of advancing Omics-based assessment and individu-
alized countermeasures, as the foundation of medicine of
the twenty first century for human space flight. This med-
icine would be personalized, preventive, predictive, and
participatory.
The new paradigm will necessarily involve Earth-based
mission-preparatory countermeasures, in-flight space-based
countermeasures, habitation space-based countermeasures,
and recovery-based countermeasures on return to Earth.
This would, at minimum, include: (1) establish the cri-
teria for ‘‘best evidence’’ that can be used to develop
individualized countermeasures today; (2) establish the
criteria for best evidence that prioritizes research, clinical
assessment, and individualized countermeasures to be
developed in the near term; (3) establish a deliberate dis-
covery path that seeks to develop sophisticated and more
complex models for long-term deployment of personalized
medicine as the standard in human space flight.
In summary, this review is not intended to proffer any
policy statement or position, but rather to explore a series
of core concepts from which personalized approaches to
enhance astronaut performance, endurance, and safety can
be developed. This new approach will require both scien-
tific and technology advances, coupled with novel imple-
mentation strategies compelled by the rigors of extended
duration missions and habitation in the final frontier. These
methods applied to the complexity of space flight are also
expected to become valuable tools, as we advance the
personalized medicine paradigm in Earth-based medicine.
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